Tesamorelin for Belly Fat: What Research Shows
Tesamorelin for belly fat is one of the few peptide questions with a real clinical paper trail, and that trail is narrower than the search phrase sounds. Tesamorelin is a synthetic analog of growth hormone-releasing hormone. In prescription form it is labeled to reduce excess abdominal fat in adults with HIV who have lipodystrophy. It is not labeled for weight loss, and it is not a general treatment for ordinary belly fat. This page summarizes what those studies reported. It is a research reference only. Research-grade material is not for human consumption.
Visceral fat is not the fat you can pinch
Visceral adipose tissue sits inside the abdominal wall, packed around the liver and intestines. Subcutaneous fat sits under the skin. The two depots do not respond the same way to hormones, diet, or drugs. Visceral fat is the depot more tightly linked to insulin resistance, higher triglycerides, and cardiovascular risk. In the tesamorelin trials, the primary endpoint was visceral fat on a CT slice around L4 to L5. It was not a mirror check, and it was not the number on a bathroom scale.
That measurement choice is why a change in these studies should not be read as spot reduction for cosmetic belly fat. A smaller waist can follow a drop in visceral volume. Scale weight often does not, because subcutaneous fat and lean mass barely move.
How a GHRH analog reaches fat tissue
Tesamorelin binds the GHRH receptor on pituitary somatotrophs and supports a pulse of growth hormone. Growth hormone then raises IGF-1 and increases lipolysis, with a relative preference for visceral adipose tissue over the subcutaneous layer. Native GHRH is cleared in minutes. The analog is modified so it lasts long enough for a once-daily research or clinical exposure. The pathway is laid out in what tesamorelin does.
CJC-1295 is another GHRH-receptor analog studied for growth hormone release, but it does not have this visceral-fat trial program. Ipamorelin raises growth hormone through the ghrelin receptor instead. A shared downstream hormone is not the same evidence. Only tesamorelin has randomized human data aimed at abdominal visceral fat, and only in a defined patient group.
What the 26-week trials reported
The pivotal evidence is two randomized, placebo-controlled phase 3 trials in adults with HIV-associated lipodystrophy, later described in pooled analyses. Participants received tesamorelin or placebo for 26 weeks. The usual labeled prescription regimen for that indication is 2 mg subcutaneously once daily. That figure is a drug-label fact for the approved product. It is not a recipe for research vials, and it is not advice to use any dose.
Across those reports, CT-measured visceral adipose tissue fell by about 15 percent from baseline in the tesamorelin arms, while placebo changed little. Subcutaneous abdominal fat did not fall in proportion. Body weight stayed roughly neutral, which is why reviewers call the effect fat redistribution in a specific condition, not weight loss. Waist circumference declined modestly, in line with the visceral change. IGF-1 rose, which is the expected pharmacodynamic marker. Some analyses also reported a modest triglyceride improvement. After treatment stopped, visceral fat tended to drift back toward baseline, so the change depended on continued exposure. A cardiovascular outcome benefit has not been demonstrated.
| Measure | Research-reported finding | Where it was seen |
|---|---|---|
| Visceral adipose tissue (CT) | About 15% lower than baseline at 26 weeks, versus little change on placebo | HIV lipodystrophy phase 3 program |
| Subcutaneous abdominal fat | Small change compared with the visceral reduction | Same trials |
| Body weight | Approximately weight-neutral | Label and trial summaries |
| IGF-1 | Increased, as expected for a GHRH analog | Same program |
| After stopping | Visceral fat tended to return toward baseline | Extension follow-up |
These are study-reported outcomes, not dosing advice and not expected results outside the population that was enrolled. Healthy adults, athletes, and people with ordinary age-related abdominal fat were not the trial population.
What the result does not support
The trials do not show that tesamorelin burns belly fat in people without HIV-associated lipodystrophy. They do not show durable loss after the exposure ends. They do not show a benefit on heart attack or stroke. Safety and efficacy are not established in anyone under 18. In the labeled setting, disrupted pituitary function, active malignancy, and pregnancy are situations where the prescription product is not used. Common effects reported in clinical use include injection-site reactions, joint or muscle pain, swelling in the hands or feet, and numbness or tingling in the hands. Those are summarized on the tesamorelin side effects page.
Research handling questions belong with the reference material, not with a personal protocol. Reported exposure figures are collected on the tesamorelin dosage page. Volume math for legitimate lab work sits on the calculator linked below.
How this compares with other GH-axis peptides
People often ask whether a ghrelin-receptor agonist would do the same thing to abdominal fat. It might raise growth hormone. It does not inherit tesamorelin's CT endpoint. There is also no clinical trial of a tesamorelin plus ipamorelin combination for visceral fat, so a blended "belly fat stack" is speculation, not a result. Read the separate research lines on their own pages rather than assuming the outcomes transfer.